“Based on these preliminary findings, we feel that acalabrutinib has promising activity in this group of patients, and safety, and it’s effective very quickly and it appears at least in the early follow-up to have durability,” said Awan, associate professor, division of hematology, department of internal medicine, Ohio State University.
onclive.com/conference-cove...
Jeff
Acalabrutinib vs Ibrutinib 
Acalabrutinib Achieved Breakthrough Designation for CLL
Survey for CLL patients having taken Venetoclax or Acalabrutinib
Newbie, Acalabrutinib for CLL as initial treatment
